IgA Nephropathy Epidemiology Summary

• IgAN is an autoimmune disease in which clusters of antibodies, primarily IgA, accumulate in the kidneys, triggering inflammation and progressive damage. These immune deposits harm the glomeruli tiny blood vessels responsible for filtering blood leading to leakage of blood and protein into the urine.
• According to DelveInsight’s analysis, IgAN reported more than 410,000 diagnosed prevalent cases in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• IgAN reported approximately 136,000 diagnosed prevalent cases in the US. Improved diagnostic practices, greater disease awareness, and wider use of kidney biopsies is expected to drive the growing prevalence of IgAN.
• IgAN is more prevalent in men than in women. Males show higher prevalence of IgAN, which may be linked to hormonal and genetic differences that influence immune response and disease progression.
• The lack of structured screening in many healthcare systems limits early diagnosis of IgAN, as routine urinalysis and renal biopsies are not widely implemented. This leads to delayed detection and missed treatment opportunities. Globally, the absence of reliable, noninvasive biomarkers further complicates early diagnosis and monitoring. Developing innovative diagnostic tools and biomarkers is essential to advance proactive, personalized IgAN management.

DelveInsight’s “IgA Nephropathy Epidemiology Forecast – 2036” report delivers an in-depth understanding of IgAN, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

IgA Nephropathy (IgAN) Understanding

IgAN Overview and Diagnosis

IgAN also known as Berger disease, is an autoimmune disease that attacks the kidneys and affects blood filtration in the kidneys’ small blood vessels. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. It is estimated that 20–40% of people with IgAN will develop end-stage kidney disease, which means they will need dialysis or kidney transplantation to survive.

The diagnosis of IgAN relies entirely on a histopathologic evaluation of renal biopsy, demonstrating mesangial hypercellularity and predominant or co-dominant glomerular deposition of IgAN, usually with complement C3 and variable amounts of IgG and/or IgM.

As part of the diagnostic process for IgAN, healthcare professionals typically assess symptoms, perform a physical examination, and order a series of laboratory tests to evaluate kidney function. Key diagnostic tools include urinalysis to detect blood or protein in the urine and the urine protein-to-creatinine ratio (UPCR), which measures total protein levels relative to creatinine. An EGFR blood test is used to assess how efficiently the kidneys are filtering waste. In many cases, a kidney biopsy is necessary to confirm the diagnosis, as it provides detailed information on tissue damage and helps predict the risk of long-term kidney failure.

Further details are provided in the report...

IgA Nephropathy (IgAN) Epidemiology

Key Findings from IgAN Epidemiological Analysis and Forecast

• In 2025, the US had the highest IgAN burden at 136,000 cases, followed by EU4 and the UK with 105,000 cases. Regional differences reflect population size and variation in biopsy practices, hematuria/proteinuria screening, healthcare infrastructure, and access to nephrology and pathology expertise.
• According to DelveInsight’s analysis, in 2025, there were approximately 80,000 male and nearly 60,000 female diagnosed prevalent cases of IgAN in the US. Sex-specific variations in IgA regulation and kidney physiology may contribute to the increased vulnerability in males.
• The 18–45 years age group accounted for the highest number of IgAN cases in Japan, with nearly 70,000 diagnosed prevalent cases. This figure is projected to rise due to improved diagnostic recognition and evolving demographic trends.

Industry Experts and Physician Views for IgA Nephropathy (IgAN)

To keep up with IgAN dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the IgAN epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others. DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Stanford University Medical Center, Division of Nephrology and Rheumatology, RWTH Aachen University, Department of Nephrology, Sorbonne Université, Nephropathy Laboratories, University of Leicester etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in IgAN.

Scope of the IgAN Epidemiology Report

• The report covers a segment of key events, an executive summary, a descriptive overview of IgAN, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

IgAN Epidemiology Report Insights

• IgAN Patient Population Forecast
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of IgAN
• Gender-specific Diagnosed Prevalent Cases of IgAN
• Age-specific Diagnosed Prevalent Cases of IgAN

IgAN Epidemiology Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

Explore DelveInsight’s IgA Nephropathy Market Forecast to 2036 for comprehensive epidemiological insights, emerging therapies, treatment trends, and future market opportunities.

FAQs

• IgAN Epidemiology Insights
• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of IgAN cases?
• What are the disease risks and burdens of IgAN?

Reasons to Buy IgAN Epidemiology Report

• The report will help in developing business strategies by understanding the latest epidemiology trends.
• Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand KOLs’ perspectives on the dynamic epidemiology trends.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.